SANTA CRUZ BIOTECHNOLOGY, INC. DDAH I (C-19): sc-26068

The Power to Question

BACKGROUND APPLICATIONS DDAH, a dimethylarginine dimethylaminohydrolase, hydrolyzes dimethyl DDAH I (C-19) is recommended for detection of DDAH I of mouse, rat and arginine (ADMA) and monomethyl arginine (MMA), both inhibitors of nitric human origin by Western Blotting (starting dilution 1:200, dilution range oxide synthases, and may be involved in in vivo modulation of nitric oxide 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution production. Impairment of DDAH causes ADMA accumulation and a reduc- range 1:50-1:500). tion in cGMP generation. DDAH II, the predominant DDAH isoform in endothelial cells, facilitates the induction of nitric oxide synthesis by all- RECOMMENDED SECONDARY REAGENTS trans-Retinoic acid (atRA). DDAH proteins are highly expressed in colon, kid- To ensure optimal results, the following support (secondary) reagents are ney, stomach and liver tissues. recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti- REFERENCES goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ 1. Nakagomi, S., et al. 1999. Dimethylarginine dimethylaminohydrolase Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: (DDAH) as a nerve-injury-associated molecule: mRNA localization in the sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluores- rat brain and its coincident up-regulation with neuronal NO synthase cence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) (nNOS) in axotomized motoneurons. Eur. J. Neurosci. 11: 2160-2166. or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with PMID 10336684 UltraCruz™ Mounting Medium: sc-24941. 2. Knipp, M., et al. 2001. Structural and functional characterization of the Zn(II) site in dimethylargininase-1 (DDAH-1) from bovine brain. Zn(II) RESEARCH USE release activates DDAH-1. J. Biol. Chem. 276: 40449-40456. For research use only, not for use in diagnostic procedures. PMID 11546769 PROTOCOLS 3. Leiper, J., et al. 2002. S-nitrosylation of dimethylarginine dimethylamino- hydrolase regulates enzyme activity: further interactions betwen nitric See our web site at www.scbt.com or our catalog for detailed protocols oxide synthase and dimethylarginine dimethylaminohydrolase. Proc. Natl. and support products. Acad. Sci USA 99: 13527-13532. 4. Lin, K.Y., et al. 2002. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylaminohydro- lase. Circulation 106: 987-992. 5. Achan, V., et al. 2002. All-trans-retinoic acid increases nitric oxide synth- esis by endothelial cells: a role for the induction of dimethylaminohydro- lase. Circ. Res. 90: 764-769. 6. Knipp, M., et al. 2003. Zn(II)-free dimethylargininase-1 (DDAH-1) is inhibit- ed upon specific Cys-S-nitrosylation. J. Biol. Chem. 278: 3410-3416. PMID 12441345 7. Swiss-Prot/TrEMBL (O94760). World Wide Web URL: http://www.expasy. ch/sprot/sprot-top.html

SOURCE DDAH I (C-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of DDAH I of human origin.

PRODUCT Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Blocking peptide available for competition studies, sc-26068 P, (100 µg pep- tide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com